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1. List publications: (a) published and not previously reported; (b) in press. Provide five reprints if not previously submitted, 
2. List all additions and deletions in professional personnel and any changes in effort. 
3. Progress Report. (See Instructions) 
1.(b) Publications:  
H. M. Deutsch, K. Green and L. H. Zalkow, "Isolation of Ocular Hypotensive Agents 
from Cannabis sativa," J. Clin. Pharmacology, in press. 
K. Green, L. H. Zalkow, H. M. Deutsch, M. E. Yablonski, N. Oliver, C. M. Symmonds 
and R. D. Elijah, "Ocular and Systemic Responses to Water Soluble Material Derived from 
Cannabis sativa," Current Eye Research, submitted. 
Presentations:  
. 	H. M. Deutsch, L. H. Zalkow and K. Green, "Isolation of Hypotensive Agents from 
Cannabis sativa," 4th International Congress for Eye Research, New York, N.Y., 
Sept. 28-Oct. 3, 1980. 
H. M. Deutsch, L. H. Zalkow and K. Green, "Isolation of Hypotensive Agents from 
Cannabis sativa," Fifth Pfizer Biomedical Research Symposium, Groton, Conn., 
Oct. 20-21, 1980. 
K. Green, L. H.Zalkow, H. M. Deutsch, M. Yablonski, N. Oliver and C. Symonds, 
"Ocular and Systemic Responses to Water Soluble Material Derived from Cannabis sativa," 
to be presented at 53rd Annual ARVO Spring Meeting, Sarasota, Fla., April 26-May 1,1981. 
2. Dr. L. Gelbaum, Research Scientist devoted 3 months and Dr. Maureen Gordon, 
Research Scientist, devoted 4 months time to this project during year 01. There were 
no other additions or deletions of professional personnel. 
3. Progress Report 
1. Objectives:  
a. 	Total project. 
(1)Isolate and characterize water soluble compound(s) from Cannabis sativa which 
on the basis of screening resul is have been shown to lower intraocular pressure in 
test animals. 
(2) Based on the results above, synthesize and/or modify the basic structural 
type to develop structural activity data and more effective compounds. 
(3) Synthesize and screen water soluble derivatives of naturally occurring 
cannabinoids. 
(4) Select and screen other plants as possible sources of compounds with IOP 
lowering activity. 
b. Current Year. 
(1) Isolate a pure compound with strong IOP lowering activity from active 
fractions. 
(2) Begin the chemical characterization of this material. 
(3) Study the mechanism of action of various active fractions in laboratory 
animals. 
(4) Start the proecess of screening other plant materials. 
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2. Studies During Current Year: 
Most of the effort has been devoted to obtaining a pure compound with 
high IOP lowering activity. Initial efforts centered on conventional liquid 
chromatography and solvent extraction techniques. The solvent extraction 
technique (solid freeze dried aqueous extract, extracted with n-butanol, 
acetone, methanol and then the water soluble material freeze dried) produced 
material of high activity which was used in subsequent studies of the mechanism 
of its action in rabbits. However, little knowledge was gained about the nature 
of the material or its purity. 
The chemical nature of the active compound(s) was partially revealed by 
dialysis experiments. The retentate, which represented about 20% of the crude 
fraction had high activity at 200pg/animal whereas the dialysate was inactive at 
the same dosage. Thus, it appeared that the active material was a high 
molecular polymer (NW > — 12,000 daltons). This was confirmed by gel filtration 
chromatography on Sephadex G-10, G-15, G-25 and G-50 on which the active material 
was eluted in the void volume. It was discovered that the ionic strength of the 
buffer was very important in these separations; ion strengths of at least 0.05M 
and, preferably, 0.30M were necessary to achieve good separations and avoid 
self aggregation. Excellent separations have been achieved on sephacryl S-200, 
which has a nominal exclusion limit of 250,000 daltons for globular proteins and 
50,000 daltons for dextrans. Considerable technical problems were encountered 
in using this resin in regards to proper choice of columns, ionic strength and 
nature of buffer and proper flow rates. However, these problems have now all 
been worked out. The retentate from dialysis clearly shows two major bands; 
one sharp peak eluting near the void volume and a broad one centered about half 
way between the void volume and the included volume. All fractions showed strong 
activity at 200 pg/animal; however the void volume material was fully active at 
1 pg/animal whereas none of the others showed activity below 5 pg/animal! 
Further screening of these fractions is in progress. It would appear that the 
high molecular weight material is nearly pure whereas the later eluting material 
is contaminated with the high molecular weight fraction and is polydisperse in 
molecular weight distribution (broad peak). 
The best method of separation now appears to be to first chromatograph the 
retentate on DEAE cellulose using 0.05M tris + 0.25M Nace at pH 6.7. The first 
material eluted from the column (least acidic) is largely high molecular weight 
and has low UV absorpance at 254 nm. The next fraction is lower molecular 
weight with much stronger UV absorbance. Continued elution gives a very small 
fraction that is very dark in color, has very strong UV absorbance and is even 
lower in molecular weight distribution. Most of the IOP lowering activity is in 
the first fraction, but this has not been fully quantitated. The ion exchange 
procedure removes, irreversibly, a considerable amount ( 	35%) of very highly 
colored low molecular weight material and is now obviously the first method of 
purification before gel filtration. We plan on using affinity chromatography 
with concanavalin A dextrose now that these purer fractions are readily available. 
Efforts to analyze and/or purify the material by gel electrophoresis have not 
met with much success to data. Conditions known to work with standard proteins 
do not work with these fractions. Thus, standard protein stains do not work 
at all, presumably due to very high carbohydrate content. Staining with periodate 
and Alcian Blue dye have shown some success and conditions are being optimized 
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for this procedure. Conditions for good separation e.g. strength of gel, 
% crosslinking, buffers and pH have not yet been worked out. When our new 
vertical slab gel unit is delivered, we expect to make rapid progress in this 
critical area of separation. We will also soon have access to a flat bed 
isoelectric focusing unit which might prove more fruitful than electrophoresis. 
Because we have only recently been able to isolate relatively pure materials, 
only limited progress has been nade in chemical characterization. The crude 
retentate shows analysis for about 50% protein - 50% carbohydrate, although 
the results are somewhat variable due to highly colored lower molecular weight 
material. 	More highly purified fractions, such as the higher molecular weight 
material from gel filtration chromatography consistently show much lower 
protein analysis, in the range 10-20%. We are quite confident that the active 
material is a high carbohydrate containing glycoprotein, as material of this 
general type has been isolated from other strains of Cannabis and recently from 
other plants. 
We expect that a major part of our effort in the next year will be in 
characterization of the pure active glycoprotein, Analysis of the number and 
type of sugars and amino acids present by standard chemical, spectroscopic, and 
chromatographic (including MS/GC) methods will be actively pursued. We also 
hope to apply recent advances in 13C NMR spectroscopy to this problem since 
the School of Chemistry has recently acquired excellent facilities in this area 
(Bruker 300 MHz multinuclear Fourier Transform instrument). The carbohydrate-
protein linkage and branching in the carbohydrate moiety will also be investigated 
by standard methods. 
Our collaborator, Dr. K. Green, at the Medical College of Georgia has made 
extensive studies of the mechanism of action of several water soluble fractions 
in lowering the IOP of rabbits and monkeys. Most of this testing was done with 
the water soluble solvent extracted fraction. Intravenous administration produced 
a dose-related fall in intraocular pressure in both albino and pigmented rabbits 
with concentrations as low as 5 pg/animal sometimes being effective, but no 
response was found in monkeys. High concentrations (0.2 to 1 mg/animal) 
induced a hyptensive phase in intraocular pressure prior to the ocular hypotension; 
higher concentrations (2 or 5 mg/animal) also induced antidiuresis and general 
relaxation. Tachyphylaxis was found in repeated daily injections. Alpha and 
8-adrenergic antagonists caused some reduction of the hypertensive phase but had 
no effect on the hypotensive phase. Superior cervical ganglionectomy did not 
influence the time course of the intraocular pressure response. Indomethacin 
inhibited the hypertensive intraocular pressure phase but was ineffective against 
the hypotensive phase. Systemic blood pressure was unchanged following intravenous 
administration of 200 pg material/animal. Aqueous humor protein concentration 
was increased at both 1 and 6 hours after intravenous administration, becoming 
greater at the later time. Aqueous humor turnover rate was substantially 
reduced reaching a minimum 8.5 hours after administration. Topical administration 
was ineffective in eyes even when the epithelium was removed in rabbits with and 
without pretreatment with aspirin. Neither gastric nor suppository administration 
of large quantities (10 mg or greater) of material had any influence on intraocular 
pressure. 
A number of other plants have been processed to give freeze dried water soluble 
extracts. Most of these have been totally inactive in lowering IOP when given 
intravenously in rabbits. However, at least two plants have shown activity 
(IOP fall of 50%) when tested at 200 pg/animal. These plants extracts have been 
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dialyzed and the retentates and dialysates are being screened for activity. 
We plan to vastly increase this phase of the project during the coming year. 
Many more plants will be screened and we plan to routinely dialyze and test 
any active material. Active samples will also be analyzed by analytical gel 
chromatography and/or gel electrophoresis. 
We have not devoted any effort during the current year to modification of 
the basic structural type. When pure active material becomes available, extensive 
studies of its chemical nature will be undertaken. Studies of this type will be 
important in the next period. Enzymatic cleavage reactions will ge given the 
greatest preference, but selected chemical modifications will also be considered. 
3. Significance to Health Problems  
In view of the fact that glaucoma is the second leading cause of blindness 
in the United States, the importance of developing new and useful drugs in this 
area is obvious. The water soluble compounds isolated from marijuana have a more 
profound effect (lower IOP by 60%) than any other known compound at any dose 
level. Therefore the potential for benefit is indeed very great. If an easy 
to deliver, safe, effective drug can be developed from this work, it would be 
a very significant advance in glaucoma therapy. In any case, due to the potency 
of action, both in regards to the large decreases in IOP and the very small 
dose levels, this material is of fundamental interest to scientists interested 
in glaucoma and the mechanism of pressure regulation. 
4. Research Goals During Coming Year  
a. Continue established separation methods, with special emphasis on ion 
exchange and affinity chromatography, gel electrophoresis and isoelectric focusing, 
until a pure active material has been isolated. 
b. Most of our effort will be geared towards the physical and chemical 
characterization of the above active fraction. 
c. Selected chemical and biological transformations of the active 
material will be attempted in order to understand which portions of the molecule 
are necessary for IOP lowering activity, and to study its mechanism of action. 
d. Screening of other plants will be increased to a considerable extent. 
e. At least one water soluble derivative of a natural Cannabinoid will 
be made and screened for activity. 
The undersigned agrees to accept responsibility 
for the scientific and technical conduct of the project 
and for provision of required progress reports if a 
grant is awarded as the result of this application. 
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